{
    "case_number": "CAC-UDRP-102067",
    "time_of_filling": "2018-06-22 08:59:38",
    "domain_names": [
        "glyxambimet.com"
    ],
    "case_administrator": "  Iveta Špiclová   (Czech Arbitration Court) (Case admin)",
    "complainant": [
        "BOEHRINGER INGELHEIM INTERNATIONAL GMBH"
    ],
    "complainant_representative": "Nameshield (Enora Millocheau)",
    "respondent": [
        "Domain Admin \/ This Domain is For Sale "
    ],
    "respondent_representative": null,
    "factual_background": "FACTS ASSERTED BY THE COMPLAINANT AND NOT CONTESTED BY THE RESPONDENT:\r\n\r\nThe Complainant is a family-owned pharmaceutical group of companies with roots going back to 1885, when it was founded by Albert Boehringer (1861-1939) in Ingelheim am Rhein. Ever since, Boehringer has become a global research-driven pharmaceutical enterprise and one of the pharmaceutical industry's top 20 companies with roughly 50,000 employees. Its three business areas are human pharmaceuticals, animal health and biopharmaceuticals. In 2017 alone, net sales of the Boehringer Group amounted to about EUR 18.1 billions .\r\n\r\nGLYXAMBI is a prescription medication containing two medicines, empagliflozin and linagliptin.  It can be used along with diet and exercise to lower blood sugar in adults with type 2 diabetes, and can be used in adults with type 2 diabetes who have known cardiovascular diseases when both empagliflozin and linagliptin are appropriate and empagliflozin is needed to reduce the risk of cardiovascular death.\r\n\r\nThe Complainant states that the disputed domain name <glyxambimet.com> is confusingly similar to its registered trademark GLYXAMBI and domain name associated.\r\n\r\nThe Complainant contends that the Respondent has no rights or legitimate interests in respect of the domain name and that the Respondent is not related in any way with the Complainant. The Complainant informs that Boehringer Group does not carry out any activity for, nor has any business with the Respondent.\r\n\r\nThe Complainant informs that the disputed domain name was registered on May 11, 2018 by the Respondent and that it points to a parked page in which said domain name is available for sale and offered for 990 USD.    ",
    "other_legal_proceedings": "No other legal proceedings are known by the Panel.",
    "no_response_filed": "NO ADMINISTRATIVELY COMPLIANT RESPONSE HAS BEEN FILED.\r\n\r\n",
    "rights": "The Complainant has, to the satisfaction of the Panel, shown the disputed domain name is identical or confusingly similar to a trademark or service mark in which the Complainant has rights (within the meaning of paragraph 4(a)(i) of the Policy).  ",
    "no_rights_or_legitimate_interests": "The Complainant has, to the satisfaction of the Panel, shown the Respondent to have no rights or legitimate interests in respect of the disputed domain name (within the meaning of paragraph 4(a)(ii) of the Policy).  ",
    "bad_faith": "The Complainant has, to the satisfaction of the Panel, shown the disputed domain name has been registered and is being used in bad faith (within the meaning of paragraph 4(a)(iii) of the Policy).  ",
    "procedural_factors": "The Panel is satisfied that all procedural requirements under UDRP were met and there is no other reason why it would be inappropriate to provide a decision.",
    "decision": "Accepted",
    "panelists": [
        "Avv. Guido Maffei"
    ],
    "date_of_panel_decision": "2018-07-27 00:00:00",
    "informal_english_translation": "The Complainant Boehringer Ingelheim International GmbH Ltd has fully proved to be the owner of the International Registration No. 1158911 for GLYXAMBI registered on March 20, 2013 and protected in numerous countries.\r\n\r\n\r\n",
    "decision_domains": {
        "GLYXAMBIMET.COM": "TRANSFERRED"
    },
    "panelist": null,
    "panellists_text": null
}